










doi:10.101Extended Follow-up of Autologous
Bone Marrow Transplantation with
4-Hydroperoxycyclophosphamide (4-HC) Purging for
Indolent or Transformed Non-Hodgkin Lymphomas
Yvette L. Kasamon,1,2 Richard J. Jones,1,2 Christopher D. Gocke,1,3 Amanda L. Blackford,1
Eric J. Seifter,1,2 Janice M. Davis-Sproul,1 Steven D. Gore,1 Richard F. Ambinder1,2,3Autologous blood or marrow transplantation (ABMT) for low-grade lymphomas can prolong event-free
survival (EFS) but requires long-term follow-up. We report one of the longest follow-ups to a prospective
transplantation study in such diseases. On a phase II study, 80 patients with low-grade, transformed, or man-
tle cell lymphoma received ABMTwith 4-hydroperoxycyclophosphamide (4-HC) purging as part of initial or
salvage therapy. Diagnoses included nontransformed follicular lymphoma in 63% and transformed lymphoma
in 15%. With 16.6-year median follow-up for survival, actuarial 10-year EFS and overall survival (OS) were
34% (95% confidence interval [CI], 25%-46%) and 45% (35%-57%). Median EFS and OS were 3.0 and 8.0
years. Early nonrelapse mortality incidence was 8%; myelodysplastic syndrome or leukemia incidence was
4%. Most relapses occurred within 3 years, with a median time to diagnosis of relapse of 1.8 years (range:
0.1-15.6 years). On multivariate analysis, age.50 years,$3 prior chemotherapy regimens, and ABMTafter
relapse were associated with significantly inferior survival. Fifteen patients (19%) were event-free.15 years
after transplantation, raising the possibility of a plateau in the progression-free survival curve. Thus, 4-HC-
purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas.
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High-dose therapy with autologous blood or mar-
rowtransplantation (ABMT)canprolongevent-free sur-
vival (EFS) in patients with follicular lymphoma (FL)
[1-4]. Numerous retrospective and prospective studies
of ABMT for indolent lymphomas have been
published. Although a few studies have suggested
a plateau in the progression-free survival curve [4-6],
others have not [7], casting doubt on its curative poten-
tial. Given the long natural history and continuous re-
lapse pattern that typify this group of diseases, mature
data are required to assess the overall therapeutic impact.1Departments of Oncology; 2Medicine; and 3Pathology,
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6/j.bbmt.2010.07.007Both lymphoma surviving the conditioning regimen
and lymphoma reintroduced at the time of bone
marrow transplantation (BMT) appear responsible for
relapse [8-10], although their relative contributions are
unknown. Tumor cells commonly can be found
circulating in the blood of patients with lymphoid
malignancies [11,12]. Moreover, syngeneic BMT
and purged ABMT appear to be associated with
lower relapse rates than unpurged ABMT [5,9,10],
further highlighting the significance of autograft
contamination. Diverse strategies have been used to
clear or purge the autograft of tumor cells, including
positive stem cell selection, in vitro treatment with
monoclonal antibodies (mAbs) or cytotoxic drugs,
and in vivo mAbs such as rituximab [9,13], although
the benefit of graft purging remains unproven
[2,14,15]. The cyclophosphamide (Cy) congener
4-hydroperoxycyclophosphamide (4-HC), and the
related compound mafosfamide, have been widely
used as cytotoxic purging agents. Inactivation of
Cy occurs almost completely via tissue aldehyde
dehydrogenase (ALDH1), which converts the metabo-
lic pathway intermediate aldophosphamide to the
noncytotoxic metabolite carboxyphosphamide [16].365
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tected against 4-HC by their high expression
of ALDH1 [16]. We report the results of a single-
institution, phase II study of 4-HC purged ABMT for
patients with a history of indolent or mantle cell
lymphoma (MCL). With a median follow-up of over
16 years in surviving patients, this is one of the longest
prospective series reported in this group of diseases to
date.PATIENTS AND METHODS
Eligibility
Between 1989 and 1994, 80 adults with biopsy-
proven non-Hodgkin lymphoma received ABMT on
a phase II clinical trial (J8913) at JohnsHopkinsUniver-
sity. The study was approved by the Johns Hopkins
institutional reviewboard, and all participants gavewrit-
ten informed consent. The following diagnoses were
eligible: nodular poorly differentiated, mixed, or large
cell lymphoma (FL, grades 1-3, respectively); diffuse
intermediate differentiated lymphoma (MCL); diffuse
well-differentiated lymphoma including chronic
lymphocytic leukemia (chronic lymphocytic leukemia/
small lymphocytic lymphoma); or diffuse poorly differ-
entiated (diffuse small cleaved cell) lymphoma (some
cases of marginal zone and MCL). Transformed lym-
phomas were not excluded. Additional requirements
included minimal or no apparent disease at the time of
BMT; #10% morphologic BM involvement by
lymphoma; white blood cell count $3000/mL; platelet
count $100,000/mL; creatinine #2.0 mg/dL; total
bilirubin #2.0 mg/dL; ejection fraction $45%; and
forced vital capacity or forced expiratory volume in 1
second of$75% predicted.
Pathology specimens in each case were reviewed by
members of the Johns Hopkins Department of Pathol-
ogy prior to study entry. Diagnoses were translated
into current World Health Organization terminology
by rereview of all available pathology reports, with
slide rereview in selected cases.
Graft Processing and Transplantation
Autografts were derived from BM harvesting. A
minimumof2108nucleatedBMcells/kgwith a target
of 4  108 nucleated BM cells/kg was collected. The
cells were treated ex vivo with 4-HC (60 mg/mL for
30 minutes) and cryopreserved until infusion. The
methods for BM processing, 4-HC purging, and
infusion have been previously published [17,18].
The preparative regimen consisted of either Cy (50
mg/kg/day intravenously [i.v.] for 4 days with uropro-
tection) and total body irradiation (TBI; 300 cGy/day
for 4 days), or busulfan (Bu; 16 mg/kg orally over 4
days, with pharmacokinetic adjustments) [19] and Cy
(50 mg/kg/day iv for 4 days) [20]. Dosing was basedon the lesser of ideal or actual body weight. Bu-Cy
was initially given in those unable to receive TBI and
later became the institutional preference. The autograft
was infused on the day after TBI or, following Bu-Cy
conditioning, 2 days after Cy (day 0).
Supportive care was delivered according to institu-
tional standard or approved research protocols and
included prophylactic vancomycin, norfloxacin, fluco-
nazole, acyclovir (if herpes simplex virus seropositive),
and trimethoprim-sulfamethoxazole or dapsone. Fun-
gal infections were treated with amphotericin B with
or without 5-flucytosine. The general platelet goal was
$20,000/mL in the absence of bleeding or anticoagula-
tion. Ten patients received 3 weeks of recombinant
human interleukin-3 beginning day 0 for augmentation
of count recovery. Granulocyte or granulocyte-
macrophage colony stimulating factorwas not routinely
given.
Endpoints
Primary induction failure was defined as nonre-
sponse to first-line therapy or disease progression
within 2 months of its completion. Lymphoid aggre-
gates in the BM or an atypical marrow lymphocytosis
without immunologic proof of clonality was catego-
rized as suspicious for involvement by lymphoma.
Retreatment with the same chemotherapy regimen,
or a change in regimen because of nonresponse, was re-
garded as a separate therapy; a change for other reasons
in a responding patient or combined modality therapy
was considered a single regimen. Remission refers to
complete remission (CR) or partial remission (PR).
Neutrophil recovery was defined as the first of 3 con-
secutive days with an absolute neutrophil count of
$500/mL. Platelet recovery was defined as the first
day with a platelet count of $20,000/mL, measured at
least 7 days from platelet transfusion.
Dates and causes of death were determined from
chart and study database review and searches of the
Social Security Death Index and National Death Index.
For the purpose of this analysis, deaths that occurred af-
ter relapse or progression were attributed to lymphoma
unless otherwise noted. In 3 such patients, the date of
relapsewas unknown andwas imputed using themedian
time between relapse and death in the other patients.
Statistics
EFS and overall survival (OS) rates with corre-
sponding95%confidence intervals (CI)were calculated
from the date of transplantation using the Kaplan-
Meier method. An event was defined as relapse or
progression,myelodysplastic syndrome (MDS)or acute
leukemia, or death from any cause. Radiographic
confirmation of remission was not required given the
lack of routine imaging beyond 5 years after BMT.
Univariate Cox proportional hazards models were
Table 1. Patient and Transplant Characteristics (n 5 80)
Characteristic Value
Median age at BMT, years (range) 47 (29-64)
Male, n (%) 47 (59%)
Diagnosis, n (%)
FL, without transformation 50 (62.5%)
FL grade 1 or 2 46
FL grade 3 4
Transformed FL* 12 (15%)
DLBCL with past or concurrent FL 9




from FL grade 1
1
DLBCL and FL grade 3† 2
DLBCL‡ 2




Marginal zone lymphoma 1
Non-Hodgkin lymphoma, unspecified 4
Low-grade versus mantle cell lymphoma 3
Low-grade lymphoma 1
Median years from diagnosis to BMT (range) 2 (0.5-9.6)
Median number of prior chemotherapy
regimens (range)
2 (1-4)
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ables and survival, with variables having a P \ .10
then included in amultivariateCoxmodel that included
a term to adjust for the time from diagnosis to BMT. A
hazard ratio (HR) .1 indicates an increased risk of
failure associated with having the variable relative to
its reference category.
Early nonrelapse mortality (NRM) was defined as
nonrelapse death within 101 days after BMT. Cumula-
tive incidences of relapse or progression, NRM, and
MDS or leukemia were estimated using competing-
risks analyses [21]; deathwithout relapse or progression
was considered a competing risk for relapse or
progression, relapse or progression was a competing
risk for NRM, and death was a competing risk for
MDS or leukemia. Prognostic factors for competing-
risk endpoints were analyzed using proportional
hazards models for competing risks [22]. All P-values
are 2-sided. Statistical analyses were performed with
R, version 2.8.0 [23] and represent data throughMarch
22, 2010.Prior radiation for lymphoma 14
Remission status at BMT, n (%)
First remission§ 29 (36%)
With primary induction failure 3
First relapse, sensitivity undetermined¶ 3
Second remission 30 (37.5%)
With primary induction failure 3
Second relapse, with active central
nervous system disease
1
Third remission 14 (17.5%)
Fourth remission or greater 3
Bone marrow involvement at BMT, n
Negative 45
Positive or suspicious 31
Unknown 4
Median graft dose (25th, 75th percentile)
Total nucleated cells  109 5.05 (3.72, 6.28)
Total nucleated cells/kg  108 0.80 (0.59, 0.97)
Preparative regimenRESULTS
Patient Characteristics
Characteristics of the patients and transplants
(n5 80) are summarized inTable 1.Themost common
diagnosis was FL without transformation (63%), with
transformed lymphomas representing 15% of cases.
Similar proportions received BMT in first or second
remission (36% and 38%, respectively) with 21%being
in third or greater remission. Over two-thirds (68%)
received Bu-Cy conditioning, with the remainder
receiving Cy-TBI.Busulfan-cyclophosphamide 54 (67.5%)
Cyclophosphamide-TBI 26 (32.5%)
BMT indicates bone marrow transplantation; FL, follicular lymphoma;
DLBCL, diffuse large B cell lymphoma; TBI, total body irradiation.
*Includes evolution of FL grade 1 or 2 to FL grade 3 lymphoma; excludes
evolution of FL grade 3 lymphoma to DLBCL.
†One case of DLBCLwith prior FL grade 3, and 1 case of FL grade 3 with
prior DLBCL.
‡These patients were eligible for study; current review of pathology
reports did not permit confirmation of transformation.
§Partial or complete remission.
¶Two untested relapses, and 1 treated relapse with radiographically
nonvaluable disease.Toxicities
Themedian time toneutrophil recoverywas 29days
(range: 16-71 days); in 1 case recovery date was un-
known, and4 additionalpatientshadnoornoconfirmed
neutrophil recovery before death or relapse. In patients
whoseneutrophil recoverywasdocumented, themedian
time to neutrophil recovery was not significantly differ-
ent in those transplanted in first remission versus after
relapse (29 and 30 days, respectively; P 5 .22). The
median time to platelet recovery was 37 days (range:
25-70 days); in 12 patients the recovery time was
unknown because of transition to outside follow-up,
and 9 additional patients had no or no confirmed recov-
ery before death or relapse with a median time to event
of 58 days (range: 35-360 days).
Nonfatal, unexpected toxicities in the early post-
transplant period included several cases of signifi-
cant upper gastrointestinal bleeding, an intracranial
bleed, and a self-limited case of idiopathic, severe dener-
vating polyneuropathy consistent with Guillan-Barre´syndrome. Severe pulmonary toxicity occurred in 4
patients; this was fatal in 2 patients and possibly contrib-
uted to death in the 2 others. There were 5 documented
cases of hepatic veno-occlusive disease, 1 of which was
fatal.
Causes of death after transplantation are summa-
rized in Table 2. Early treatment-related mortality
occurred in 6 patients. Five additional deaths within
the first year were related or possibly related to trans-
plantation, all in patients transplanted beyond first
Table 2. Mortality After Transplantation
Early Treatment-Related Mortality (Survival Time) N
Sepsis (58 days, 101 days) 2
Pulmonary toxicity (40 days, 57 days) 2
Sudden death, possibly from pulmonary toxicity (61 days) 1
Veno-occlusive disease, multiorgan failure (48 days) 1
Other nonrelapse deaths during first year
Cytomegalovirus pneumonitis (3.8 months) 1
Sepsis after slow engraftment (4.5 months) 1
Viral hepatitis (7.7 months) 1
Idiopathic pancytopenia, rash, altered mental status
(11.5 months)
1
Hemorrhagic stroke with thrombocytopenia (11.8 months) 1
Remaining causes of death
Recurrent non-Hodgkin lymphoma 31
Hodgkin lymphoma, after relapse of non-Hodgkin lymphoma 1
Myelodyplastic syndrome or acute leukemia
(6.1, 7.3, 15.0 years)
3
Solid tumor* 4
Complications after renal transplantation 1
Late sepsis 1
*Presumed cause of death in 1.
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14% in the first year, with an 8% incidence of early
NRM. Three cases of MDS or acute myelogenous
leukemia were identified (2 after Bu-Cy and 1 after
Cy-TBI), with a cumulative incidence of 4% (95%
CI, 0%-9%); these were diagnosed at 5.0 years, 6.4
years, and 14.4 years after BMT and occurred in
patients transplanted in first remission without subse-
quent relapse of lymphoma.Clinical Outcomes
Disease and survival outcomes for the group
overall are shown in Figure 1. At last assessment, 28
patients (35%) were alive, including 9 whose disease
relapsed or progressed after BMT. Forty-one patients
had relapsed or progressed. Fifty-two patients had
died, 32 after having relapsed or progressive lym-
phoma (Table 2).
With a median follow-up of 16.6 years in patients
without events (range: 6.7-20.1 years) and 3.5 years
(range: 0.1-20.1 years) overall, the actuarial EFS at 5
years and 10 years after BMT was 45% (95% CI,
35%-57%) and 34% (25%-46%) respectively; the
median EFS was 3.0 years (Figure 1A).
Of the 28 surviving patients, all but 1 (96%) had
greater than 10-year follow-up for vital status after
transplantation, and 25 patients (89%) had .15-year
follow-up. With a median follow-up of 16.6 years in
surviving patients (range: 6.7-20.1 years) and 7.7 years
(range: 0.1-20.1 years) for all patients, the actuarial OS
at 5 years and 10 years after BMT was 57% (95% CI,
48%-69%) and 45% (35%-57%), respectively; the
median OS was 8.0 years (Figure 1A).
The estimated cumulative incidence of relapse or
progression was 39% (95% CI, 28%-50%) at 5 years
and 48% (95% CI, 37%-59%) at 10 years on
competing-risk analysis (Figure 1B). Of the 38 patients
whose relapse date was confirmed, the median time todiagnosis of relapse after BMT was 1.8 years (range:
0.1-15.6 years). Twenty-eight of these patients (74%)
had relapse identified within the first 3 years. Nine
patients (one with MCL, the remainder with low-
grade FL) relapsed more than 7 years after BMT, and
3 (all with low-grade FL) relapsed more than 12 years
after BMT. The median time from diagnosis of
relapse after BMT to death was 1.7 years (range:
0.1-12.1 years).
Disease-specific survival estimates are shown in
Figure 2 and Table 3. Of the 19 patients who were
event-free, 9 were transplanted in CR1 or PR1 and 14
had a documented history of low-grade FL, including
3 with transformations (Figure 2A-D). Of the 12 pa-
tients with transformations, all from low-grade FL, 3
were event-free at 15.6-17.8 years after BMT, 2 had
nonrelapse deaths (at 1 year and 10.3 years), and the
remainder died of lymphoma at 0.1-4.3 years after
BMT (Figure 2E and F). Of the 5 MCL patients, 1
remained event-free at 18.4 years after BMT and 4
relapsed at 1.6-9.6 years. Fifteen patients (19%) were
event-free more than 15 years after BMT, of which 9
were transplanted in first remission, 5 in second remis-
sion, and 5 in third or greater remission.
Outcome Variables
A post hoc analysis of variables in relation to
transplantation outcomes is presented in Table 4. On
univariate analysis, no significant association was
found between survival outcomes and time from
diagnosis to BMT, having transformed lymphoma,
having BM involvement prior to transplantation, or re-
ceiving Bu-Cy versus Cy-TBI conditioning. On unad-
justed analysis, age .50 years at BMT was associated
with a tendency toward greater risk of relapse or pro-
gression (HR 1.73, 95% CI 0.9-3.32, P5 .10) without
a significantly greater risk of NRM (HR 1.48, 95% CI
0.61-3.6, P 5 .38). On multivariate analysis, age .50
years was associated with a statistically significantly in-
ferior EFS and OS, as was having 3 or more prior che-
motherapy regimens and BMT after relapse. The
results of univariate and multivariate analyses of EFS
and OS were similar in patients with FL inclusive of
transformations (data not shown); this included, on
multivariate analysis, age and number of prior chemo-
therapy regimens being significantly associated with
EFS and OS, and BMT after relapse being associated
with a significantly inferior EFS (HR 3.83, 95% CI
1.23-11.1, P 5 .02) and tendency toward inferior OS
(HR 2.56, 95% CI 0.82-8.33, P 5 .11) compared
with BMT in CR1 or PR1.DISCUSSION
We report encouraging long-term outcomes of pa-
tients with B-cell lymphoma treated with high-dose
Figure 1. Long-term outcomes after transplantation for the entire group. (A) EFS and OS and (B) cumulative incidence of progression or relapse based
on competing-risk analysis. Dotted lines represent 95% CIs.
Biol Blood Marrow Transplant 17:365-373, 2011 3694-HC-Purged ABMTtherapy and 4-HC-purged ABMT. With a median
follow-up of over 16 years in surviving patients, this
is one of the most mature transplantation series re-
ported in this group of diseases.
Most cases of relapse or progression were
identified within the first 3 years. The EFS (45% at 5
years) is similar to that of other studies [24-26]. Few
relapses were diagnosed more than 10 years after
transplantation, although 1 relapse was diagnosed at
more than 15 years. The occurrence of late relapses
in our study underscores the importance of long-
term data when assessing transplantation outcomes
for these histologies.
It is recognized that a fraction of such patients can
enjoy long-term clinical remissions after conventional-dose or intensified therapies. Some mature studies
of ABMT [4-6,24,26] have reported a plateau or
a possibility of plateau in the disease-free survival
(DFS) curve for FL, but not others [7]. The pattern of
relapsemightbebest thoughtof asbiphasicwith anearly
high risk period followed by a much lower risk late pe-
riod [26]. If a biphasic model is appropriate, our results
suggest the possibility thatmany, or perhapsmost of the
19% of patients who remain in continuous CR more
than 15 years after transplantation will ultimately die
of causes other than lymphoma. The favorable outcome
of such patients may be because of an inherently better
biology of disease (although a subset were transplanted
after 1 or more relapses), a beneficial impact of dose
intensity, or a combination thereof.
Figure 2. Transplantation outcomes in follicular lymphoma (FL). (A) EFS and OS and (B) cumulative incidence of progression or relapse for patients
with FL including transformed lymphoma. (C) EFS and OS and (D) cumulative incidence of progression or relapse for patients with FL including trans-
formed lymphoma, transplanted in first remission. (E) EFS and OS and (F) cumulative incidence of progression or relapse for patients with transformed
FL. Cumulative incidences of progression or relapse are based on competing-risk analyses. Dotted lines represent 95% CIs.
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Table 3. Disease-Specific Survival Outcomes After Transplantation
Diagnosis N 5-year EFS, % 95% CI 5-year OS, % 95% CI 10-year EFS, % 95% CI 10-year OS, % 95% CI
FL, without transformation* 50 44 32-60 56 44-72 31 21-47 44 32-60
Any FL† 62 42 31-56 56 45-70 32 22-46 45 34-59
Any FL, BMT in first remission 20 60 42-86 75 58-97 45 28-73 65 47-90
Any FL, BMTafter relapse 42 33 22-51 48 35-65 26 15-43 35 23-53
Transformed FL 12 33 15-74 58 36-94 33 15-74 50 28-88
BMT indicates bone marrow transplantation; CI, confidence interval; EFS, event-free survival; FL, follicular lymphoma; OS, overall survival.
*FL categories exclude two patients with histories of both FL grade 3 and diffuse large B cell lymphoma.
†With or without transformation.
Biol Blood Marrow Transplant 17:365-373, 2011 3714-HC-Purged ABMTLimitations of this study include the biases inherent
to a single-institution study and the heterogeneity
of diagnoses and prior therapies. The latter has
been addressed in part by a separate analysis of FL out-
comes. For FL patients and the group overall, having
fewer than 3 prior chemotherapy regimens was associ-
atedwith improved outcomes, as was transplantation in
first remission. This is consistent with a number of
other studies [5,7,27], as is the observed negative
impact of older age [5,7,9,25,27]. However, in a more
recent phase II trial of ABMT with pre- and
posttransplantation rituximab for low-grade or MCL,
we found no statistically significant difference with
transplantation in first remission versus after relapse
[28]. Several randomized trials of high-dose therapy
and ABMT [1-4], but not all [29], have demonstrated
prolongation of EFS in subgroups of patients with
FL. The observed impact on OS has been variable
and may depend on the timing of transplantation, as
randomized trials have found a survival benefit in
patients with FL in the relapsed [2] but not frontline
setting [1,4,29]. Because patients are often followed
clinically rather than radiographically years after
transplantation, some patients believed to be disease-
free may have asymptomatic active disease.
Our 1-armed prospective study of BM purging and
high-dose therapy in consecutive patients finishedTable 4. Univariate and Multivariate Analyses of Transplantation O
Model Hazard Ratio for EFS
Univariate
Age at BMT >50 (versus #50)* 2.34
Time from diagnosis to BMT >1 year (versus #1 year) 0.63
Transformed lymphoma (versus not transformed) 1.13
Bone marrow pos or suspicious at BMT (versus neg) 1.25
BMTafter relapse (versus in first remission) 1.79
$3 prior chemotherapy regimens (versus fewer) 2.78
Bu-Cy conditioning (versus Cy-TBI) 1.26
Multivariate†
Age at BMT >50 years (versus #50 years) 2.43
BMTafter relapse (versus in first remission)‡ 2.86
Multivariate†
Age at BMT >50 years (versus #50 years) 2.45
$3 prior therapies (versus fewer)‡ 2.70
BMT indicates bone marrow transplantation; Bu, busulfan; CI, confidence inte
overall survival; pos, positive; TBI, total body irradiation.
*Variables in parentheses represent the reference categories.
†Adjusted for time from diagnosis to BMT.
‡Examined in separate models because of colinearity.accrual before the rituximab era. As such, it cannot ad-
dress whether and how this ABMT strategy compares
to transplant or nontransplant strategies in a similar pa-
tient population treated with more contemporary regi-
mens. The study does, however, shed light on issues
that may help to guide or interpret future therapies.
First, concern has been raised that in vitro purging
may increase the rate of secondary hematologic neo-
plasms [4]. Nevertheless, high-dose Cy treatment,
including treatment of BM cells in vitro, was not associ-
ated with an alarming incidence of secondary MDS or
leukemia in this study; our observed incidence (4%) is
in keeping with or lower than in other series [25]. Short
exposures to Cy or its metabolites even at high doses
may be of less concern than chronic exposures. This
study with long-term follow-up that includes lightly
pretreated patients may provide an upper bound for
the risks of MDS and acute leukemia associated with
high-dose therapy. Second, a substantial subset of pa-
tients achieved long-term clinical remissions including
patients with transformed lymphoma. As therapies
that include maintenance of various sorts are evaluated
in the treatment of such patients, these results provide
one of the longest term follow-ups of ABMT without
the use of mAb therapy.
The impact of autograft purging remains undefined.
4-HC purging may have contributed to delayedutcomes
95% CI P-Value Hazard Ratio for OS 95% CI P-Value
1.38-3.97 .002 2.75 1.57-4.83 .0004
0.33-1.21 .17 0.52 0.25-1.12 .09
0.56-2.29 .74 0.90 0.41-2.01 .80
0.74-2.10 .41 1.21 0.69-2.13
1.04-3.03 .03 1.72 0.95-3.03 .07
1.52-5.00 .0009 3.23 1.75-6.25 .0002
0.73-2.20 .41 0.86 0.48-1.52 .60
1.39-4.22 .002 2.90 1.62-5.19 .0003
1.25-6.67 .01 2.56 1.08-6.25 .03
1.38-4.36 .002 2.95 1.62-5.39 .0004
1.41-5.00 .003 3.33 1.69-6.67 .0004
rval; Cy, cyclophosphamide; EFS, event-free survival; neg, negative; OS,
372 Biol Blood Marrow Transplant 17:365-373, 2011Y. L. Kasamon et al.engraftment in some patients in our study. The time to
count recovery is similar to other studies of in vitro-
purged BMT [30,31]. Although polymerase chain
reaction has been used to assess physical removal of
tumor cells from stem cell grafts such as is achieved
with column separation or mAbs, this approach is not
readily applicable to the assessment of the effects of
chemotherapeutic agents because cell death may not
be immediate [32,33]. In early studies of leukemia and
lymphoma, fewer colony-forming unit-granulocyte
macrophages postpurging, as a measure of 4-HC or
mafosfamide activity, were associated with improved
disease outcomes [15,33]. Some other studies of
lymphoma have also indirectly suggested a benefit to
purging [9,15,34]; others have not [2,14]. Analyses of
autograft purging are partly confounded by the
inclusion of numerous different methodologies, which
may or may not have similar efficacies. It is well
recognized that eradication of residual disease from
the autograft is prognostically significant [35,36]; this
could reflect more favorable disease biology, a true
benefit of the purging procedure, or both.
These results demonstrate that very durable clinical
remissions could be achieved in a subset of patients after
high-dose therapy and ABMT. Although the impact
purging played in the outcome will remain unclear,
these data do suggest that ABMT may produce
extended DFS and possibly cure in a subset of patients
with indolent lymphomas.ACKNOWLEDGMENTS
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